GSK
GSK plc
+0.49 (+0.97%)50.78USD1.4M成交股數–市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-10-28下次財報
公司文件 SEC EDGAR 申報索引 · 全部連到 SEC 原件 · 本站不存文字
財報新聞稿(8-K Item 2.02 的 EX-99)是 guidance 與 non-GAAP 數字的出處;投資人簡報是法說會投影片;逐字稿是第三方整理的外部連結。
財報季必讀有新聞稿或簡報附件的申報
| 申報日 | 表格 | 附件 |
|---|---|---|
| 沒有分類過的附件。 | ||
全部申報 最近 120 筆
| 申報日 | 表格 | 類型 | 期末 | 內容 |
|---|---|---|---|---|
| 2026-09-15 | 6-K | 外國發行人臨時報告 | 2026-09-15 | GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA |
| 2026-09-15 | 6-K | 外國發行人臨時報告 | 2026-09-15 | 6-K |
| 2026-09-14 | 6-K | 外國發行人臨時報告 | 2026-09-14 | JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC |
| 2026-09-14 | 6-K | 外國發行人臨時報告 | 2026-09-14 | RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA |
| 2026-09-11 | 6-K | 外國發行人臨時報告 | 2026-09-11 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-09-10 | 6-K | 外國發行人臨時報告 | 2026-09-10 | JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE |
| 2026-09-10 | 6-K | 外國發行人臨時報告 | 2026-09-10 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-09-09 | 6-K | 外國發行人臨時報告 | 2026-09-09 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-09-09 | 6-K | 外國發行人臨時報告 | 2026-09-09 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-09-08 | 6-K | 外國發行人臨時報告 | 2026-09-08 | 6-K |
| 2026-09-01 | 6-K | 外國發行人臨時報告 | 2026-09-01 | TOTAL VOTING RIGHTS |
| 2026-09-01 | 6-K | 外國發行人臨時報告 | 2026-09-01 | MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III |
| 2026-08-26 | 6-K | 外國發行人臨時報告 | 2026-08-26 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-08-24 | 6-K | 外國發行人臨時報告 | 2026-08-24 | US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER |
| 2026-08-24 | 6-K | 外國發行人臨時報告 | 2026-08-24 | FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN |
| 2026-08-24 | 6-K | 外國發行人臨時報告 | 2026-08-24 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-08-18 | 6-K | 外國發行人臨時報告 | 2026-08-18 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-08-13 | 6-K | 外國發行人臨時報告 | 2026-08-13 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-08-11 | 6-K | 外國發行人臨時報告 | 2026-08-11 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-08-03 | 6-K | 外國發行人臨時報告 | 2026-08-03 | TOTAL VOTING RIGHTS |
| 2026-07-30 | 6-K | 外國發行人臨時報告 | 2026-07-30 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-07-28 | 6-K | 外國發行人臨時報告 | 2026-07-28 | HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ |
| 2026-07-28 | 6-K | 外國發行人臨時報告 | 2026-07-28 | NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE |
| 2026-07-28 | 6-K | 外國發行人臨時報告 | 2026-07-28 | 2ND QUARTER RESULTS |
| 2026-07-24 | 6-K | 外國發行人臨時報告 | 2026-07-24 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-07-24 | 6-K | 外國發行人臨時報告 | 2026-07-24 | ADMISSION TO TRADING |
| 2026-07-22 | 6-K | 外國發行人臨時報告 | 2026-07-22 | JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS |
| 2026-07-20 | 6-K | 外國發行人臨時報告 | 2026-07-20 | BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE |
| 2026-07-17 | 6-K | 外國發行人臨時報告 | 2026-07-17 | CAMLIPIXANT PHASE III RESULTS UPDATE |
| 2026-07-17 | 6-K | 外國發行人臨時報告 | 2026-07-17 | AUDIT TENDER CONCLUSION |
| 2026-07-16 | 6-K | 外國發行人臨時報告 | 2026-07-16 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-07-15 | 6-K | 外國發行人臨時報告 | 2026-07-15 | GSK COMPLETES ACQUISITION OF NUVALENT, INC |
| 2026-07-14 | 6-K | 外國發行人臨時報告 | 2026-07-14 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-07-13 | 6-K | 外國發行人臨時報告 | 2026-07-13 | POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER |
| 2026-07-13 | 6-K | 外國發行人臨時報告 | 2026-07-13 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-07-10 | 6-K | 外國發行人臨時報告 | 2026-07-10 | HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ |
| 2026-07-09 | 6-K | 外國發行人臨時報告 | 2026-07-09 | DIRECTORATE CHANGE |
| 2026-07-09 | 6-K | 外國發行人臨時報告 | 2026-07-09 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-07-01 | 6-K | 外國發行人臨時報告 | 2026-07-01 | TOTAL VOTING RIGHTS |
| 2026-06-29 | 6-K | 外國發行人臨時報告 | 2026-06-29 | HOLDING(S) IN COMPANY |
| 2026-06-29 | 6-K | 外國發行人臨時報告 | 2026-06-29 | TRANSACTION IN OWN SHARES |
| 2026-06-26 | 6-K | 外國發行人臨時報告 | 2026-06-26 | HOLDING(S) IN COMPANY |
| 2026-06-24 | 6-K | 外國發行人臨時報告 | 2026-06-24 | GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENT |
| 2026-06-24 | 6-K | 外國發行人臨時報告 | 2026-06-24 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-06-23 | 6-K | 外國發行人臨時報告 | 2026-06-23 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-06-22 | 6-K | 外國發行人臨時報告 | 2026-06-22 | TRANSACTION IN OWN SHARES |
| 2026-06-17 | 6-K | 外國發行人臨時報告 | 2026-06-17 | CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA |
| 2026-06-15 | 6-K | 外國發行人臨時報告 | 2026-06-15 | TRANSACTION IN OWN SHARES |
| 2026-06-12 | 6-K | 外國發行人臨時報告 | 2026-06-12 | MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXAS |
| 2026-06-11 | 6-K | 外國發行人臨時報告 | 2026-06-11 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-06-10 | 6-K | 外國發行人臨時報告 | 2026-06-10 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-06-09 | 6-K | 外國發行人臨時報告 | 2026-06-09 | DR HAL BARRON - NEW DIRECTORSHIP |
| 2026-06-09 | 6-K | 外國發行人臨時報告 | 2026-06-09 | GSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC. |
| 2026-06-08 | 6-K | 外國發行人臨時報告 | 2026-06-08 | TRANSACTION IN OWN SHARES |
| 2026-06-01 | 6-K | 外國發行人臨時報告 | 2026-06-01 | TOTAL VOTING RIGHTS |
| 2026-06-01 | 6-K | 外國發行人臨時報告 | 2026-06-01 | TRANSACTION IN OWN SHARES |
| 2026-05-28 | 6-K | 外國發行人臨時報告 | 2026-05-28 | POSITIVE PHASE 3 DATA FOR BEPIROVIRSEN |
| 2026-05-27 | 6-K | 外國發行人臨時報告 | 2026-05-27 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-05-26 | 6-K | 外國發行人臨時報告 | 2026-05-26 | ADMISSION TO TRADING |
| 2026-05-26 | 6-K | 外國發行人臨時報告 | 2026-05-26 | TRANSACTION IN OWN SHARES |
| 2026-05-22 | 6-K | 外國發行人臨時報告 | 2026-05-22 | Q2 2026 RESULTS DATE CONFIRMED - 28 JULY 2026 |
| 2026-05-20 | 6-K | 外國發行人臨時報告 | 2026-05-20 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-05-20 | 6-K | 外國發行人臨時報告 | 2026-05-20 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-05-19 | 6-K | 外國發行人臨時報告 | 2026-05-19 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-05-18 | 6-K | 外國發行人臨時報告 | 2026-05-18 | JAPAN MHLW APPROVES AREXVY FOR ADULTS 18-49 AIR |
| 2026-05-18 | 6-K | 外國發行人臨時報告 | 2026-05-18 | TRANSACTION IN OWN SHARES |
| 2026-05-14 | 6-K | 外國發行人臨時報告 | 2026-05-14 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-05-11 | 6-K | 外國發行人臨時報告 | 2026-05-11 | GSK - FINAL TRANCHE OF SHARE BUYBACK PROGRAMME |
| 2026-05-11 | 6-K | 外國發行人臨時報告 | 2026-05-11 | COLLABORATION WITH CTTQ FOR BEPIROVIRSEN |
| 2026-05-11 | 6-K | 外國發行人臨時報告 | 2026-05-11 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-05-06 | 6-K | 外國發行人臨時報告 | 2026-05-06 | RESULT OF AGM |
| 2026-05-05 | 6-K | 外國發行人臨時報告 | 2026-05-05 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-05-01 | 6-K | 外國發行人臨時報告 | 2026-05-01 | TOTAL VOTING RIGHTS |
| 2026-05-01 | 6-K | 外國發行人臨時報告 | 2026-05-01 | HOLDING(S) IN COMPANY |
| 2026-04-29 | 6-K | 外國發行人臨時報告 | 2026-04-29 | 1ST QUARTER RESULTS |
| 2026-04-29 | 6-K | 外國發行人臨時報告 | 2026-04-29 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-04-28 | 6-K | 外國發行人臨時報告 | 2026-04-28 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-04-28 | 6-K | 外國發行人臨時報告 | 2026-04-28 | BEPIROVIRSEN PRIORITY REVIEW US FILING ACCEPTANCE |
| 2026-04-27 | 6-K | 外國發行人臨時報告 | 2026-04-27 | TESARO UPDATE ON ANAPTYSBIO INC. LITIGATION |
| 2026-04-27 | 6-K | 外國發行人臨時報告 | 2026-04-27 | EFIMOSFERMIN GRANTED US/EU REGULATORY DESIGNATIONS |
| 2026-04-24 | 6-K | 外國發行人臨時報告 | 2026-04-24 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-04-23 | 6-K | 外國發行人臨時報告 | 2026-04-23 | TRANSACTION IN OWN SHARES |
| 2026-04-22 | 6-K | 外國發行人臨時報告 | 2026-04-22 | TRANSACTION IN OWN SHARES |
| 2026-04-21 | 6-K | 外國發行人臨時報告 | 2026-04-21 | TRANSACTION IN OWN SHARES |
| 2026-04-20 | 6-K | 外國發行人臨時報告 | 2026-04-20 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-04-20 | 6-K | 外國發行人臨時報告 | 2026-04-20 | BLENREP APPROVED IN CHINA FOR 2L+ MULTIPLE MYELOMA |
| 2026-04-20 | 6-K | 外國發行人臨時報告 | 2026-04-20 | TRANSACTION IN OWN SHARES |
| 2026-04-17 | 6-K | 外國發行人臨時報告 | 2026-04-17 | TRANSACTION IN OWN SHARES |
| 2026-04-16 | 6-K | 外國發行人臨時報告 | 2026-04-16 | TRANSACTION IN OWN SHARES |
| 2026-04-16 | 6-K | 外國發行人臨時報告 | 2026-04-16 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-04-15 | 6-K | 外國發行人臨時報告 | 2026-04-15 | TRANSACTION IN OWN SHARES |
| 2026-04-15 | 6-K | 外國發行人臨時報告 | 2026-04-15 | GSK COMPLETES ACQUISITION OF 35PHARMA INC. |
| 2026-04-14 | 6-K | 外國發行人臨時報告 | 2026-04-14 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-04-14 | 6-K | 外國發行人臨時報告 | 2026-04-14 | TRANSACTION IN OWN SHARES |
| 2026-04-13 | 6-K | 外國發行人臨時報告 | 2026-04-13 | TRANSACTION IN OWN SHARES |
| 2026-04-13 | 6-K | 外國發行人臨時報告 | 2026-04-13 | GSK PRESENTS POSITIVE DATA FOR BEHOLD 1 B7 H4 ADC |
| 2026-04-13 | 6-K | 外國發行人臨時報告 | 2026-04-13 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-04-10 | 6-K | 外國發行人臨時報告 | 2026-04-10 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-04-10 | 6-K | 外國發行人臨時報告 | 2026-04-10 | TRANSACTION IN OWN SHARES |
| 2026-04-09 | 6-K | 外國發行人臨時報告 | 2026-04-09 | TRANSACTION IN OWN SHARES |
| 2026-04-09 | 6-K | 外國發行人臨時報告 | 2026-04-09 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-04-08 | 6-K | 外國發行人臨時報告 | 2026-04-08 | EXDENSUR APPROVED FOR CRSWNP IN CHINA |
| 2026-04-08 | 6-K | 外國發行人臨時報告 | 2026-04-08 | TRANSACTION IN OWN SHARES |
| 2026-04-07 | 6-K | 外國發行人臨時報告 | 2026-04-07 | TRANSACTION IN OWN SHARES |
| 2026-04-02 | 6-K | 外國發行人臨時報告 | 2026-04-02 | TRANSACTION IN OWN SHARES |
| 2026-04-01 | 6-K | 外國發行人臨時報告 | 2026-04-01 | VIIV COMPLETES CHANGES TO MINORITY SHAREHOLDING |
| 2026-04-01 | 6-K | 外國發行人臨時報告 | 2026-04-01 | TRANSACTION IN OWN SHARES |
| 2026-04-01 | 6-K | 外國發行人臨時報告 | 2026-04-01 | TOTAL VOTING RIGHTS |
| 2026-04-01 | 6-K | 外國發行人臨時報告 | 2026-04-01 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-03-31 | 6-K | 外國發行人臨時報告 | 2026-03-31 | TRANSACTION IN OWN SHARES |
| 2026-03-30 | 6-K | 外國發行人臨時報告 | 2026-03-30 | EXDENSUR APPROVED FOR SEVERE ASTHMA IN CHINA |
| 2026-03-30 | 6-K | 外國發行人臨時報告 | 2026-03-30 | BEPIROVIRSEN ACCEPTED FOR REVIEW IN CHINA |
| 2026-03-30 | 6-K | 外國發行人臨時報告 | 2026-03-30 | TRANSACTION IN OWN SHARES |
| 2026-03-27 | 6-K | 外國發行人臨時報告 | 2026-03-27 | TRANSACTION IN OWN SHARES |
| 2026-03-27 | 6-K | 外國發行人臨時報告 | 2026-03-27 | BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA |
| 2026-03-26 | 6-K | 外國發行人臨時報告 | 2026-03-26 | TRANSACTION IN OWN SHARES |
| 2026-03-25 | 6-K | 外國發行人臨時報告 | 2026-03-25 | NOTICE OF AGM |
| 2026-03-25 | 6-K | 外國發行人臨時報告 | 2026-03-25 | DIRECTOR/PDMR SHAREHOLDING |
| 2026-03-25 | 6-K | 外國發行人臨時報告 | 2026-03-25 | TRANSACTION IN OWN SHARES |
| 2026-03-24 | 6-K | 外國發行人臨時報告 | 2026-03-24 | TRANSACTION IN OWN SHARES |